Eli Lilly stock consolidates near $1,100 with continued bullish momentum supported by MACD: weekly forecast

Traders Union
All News
Financial News
Eli Lilly rises 0.59% this week

Highlights

Eli Lilly maintains strong medium- and long-term bullish momentum, with price sustained above key moving averages.
Technical indicators collectively signal a clear bullish bias, though oscillators warn of an overbought condition and potential near-term exhaustion.
Price is projected to trade between $1,074 and $1,140 in the upcoming week, with a high probability of continued gains barring a break below support.

Strategic acquisitions and partnerships drive sentiment over the week

Eli Lilly declared a third-quarter 2026 dividend of $1.73 per share, set to be paid on September 10, 2026, to shareholders of record as of August 14, 2026. The company also received court approval in England and Wales for its acquisition of Centessa Pharmaceuticals, offering up to $47.00 per share including a $38.00 cash payment and a potential $9.00 contingent value right. In addition, Lilly entered a research and collaboration agreement with BioArctic to combine BrainTransporter technology with its neurodegeneration drug candidate, and announced three acquisitions totaling $3.83 billion to strengthen its position in vaccines and infectious diseases.

Momentum signals stay bullish as overbought readings caution near-term

On the weekly chart, all key moving averages (MA-20, MA-50, and MA-200) are sloping upward and price action remains comfortably above these support levels, with the MA-20 acting as the nearest dynamic floor. Weekly MACD and ADX both indicate continued positive momentum, while RSI at 61.15 and CCI support moderately bullish conditions without signs of excess. However, signals from Stochastic RSI and Bull/Bear Power suggest the asset is in an overbought zone, increasing the risk of short-term exhaustion even as underlying momentum remains strong.

Sideways bias expected as breakout and support thresholds watched next week

For the upcoming five trading days, LLY is projected to move within a weekly range between $1,074 and $1,140, following the recent steady performance and historical volatility of 3.00%. With all major weekly indicators (RSI, MACD, ADX, CCI) signaling a 'Buy', the base case anticipates continued sideways consolidation, with a higher probability of gains than declines. A confirmed breakout above $1,140 could open the door to additional upside, while a drop below $1,074 may indicate short-term weakness and trigger a test of lower support.

Anton Kharitonov, expert at Traders Union, sees Eli Lilly maintaining its overall bullish structure this week. The price persistently holds above all major moving averages, showing support from buyers and validating the uptrend. However, the analyst notes that multiple oscillators point to overbought territory, which raises concerns about the sustainability of this momentum in the coming week. Recent company news — including strategic acquisitions and partnership agreements — reinforces the fundamental strength, but technical risk of near-term exhaustion is evident. Kharitonov believes sideways movement is most likely, with the range between $1,074 and $1,140 acting as the main battleground for bulls and bears. "I remain cautious this week — unless price can break above $1,140, the risk of a pullback or continued consolidation remains elevated."

Earlier, analysts noted that Eli Lilly was leveraging robust cash flow from its leading obesity and diabetes treatments to accelerate investments in artificial intelligence strategic acquisitions and research collaborations aimed at expanding its drug development pipeline. The latest series of acquisitions and partnerships, combined with technical strength and ongoing bullish momentum, now place particular significance on the upcoming $1,140 resistance level, where a breakout could signal further upside potential for LLY.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.